

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Myelodysplastic syndrome with del (5q) and JAK2V617F mutation transformed to acute myeloid leukaemia with complex karyotype

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1609147> since 2016-10-31T14:23:11Z

Published version:

DOI:10.1007/s00277-015-2584-8

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Ann Hematol (2016) 95:525–527

DOI 10.1007/s00277-015-2584-8

Achille Pich, Laura Godio, Ludovica Riera, Cristina Cavaliere, Simonetta Kerim,

Lisa Bonello, Paola Francia di Celle

The definitive version is available at:

La versione definitiva è disponibile alla URL:

<http://link.springer.com/article/10.1007%2Fs00277-015-2584-8>

1 Myelodysplastic syndrome with del (5q) and JAK2V617F mutation transformed to acute myeloid leukaemia
2 with complex karyotype

3 Achille Pich, Laura Godio, Ludovica Riera, Cristina Cavaliere, Simonetta Kerim, Lisa Bonello, Paola Francia di
4 Celle1

5
6
7 Department of Molecular Biotechnology and Health Sciences, Section of Pathology, University of Torino,
8 Turin, Italy. 1Center for Experimental Research and Medical Studies (CERMS), Turin.

9
10 Corresponding author:

11 Achille Pich, MD

12
13 Department of Molecular Biotechnology and Health Sciences, Section of Pathology, University of Turin, Via
14 Santena 7, I-10126 Torino, Italy.

15
16 Tel: 39 011 6334282

17
18 FAX: 39 011 6635267

19
20 Email:achille.pich@unito.it

21
22
23 Myelodysplastic syndrome with isolated del (5q) and JAK2V617F mutation is a distinct entity within the World
24 Health Organization (WHO) category myelodysplastic syndromes (MDS) [1]

25
26 JAK2V617F is a gain of function mutation, typically associated with myeloproliferative neoplasms (MPN) [2].
27 However, approximately 5% of patients with isolated del (5q) also harbours the JAK2V617F mutation [3,4].

28
29 No correlation was found between isolated del (5q) JAK2V617F mutated cases and clinical presentation,
30 morphological features, disease transformation or patient outcome [4,5], although a few cases presented
31 with higher platelet and WBC count [3]. Lenalidomide was reported to be an effective treatment for the
32 disease [6].

33
34 We have recently studied a patient with del (5q) and JAK2V617F mutation transformed to acute
35 myeloid leukaemia (AML) with complex karyotype and increased JAK2V617F mutation load.

36
37 A 66 year old female presented with moderate anaemia and high platelet count (haemoglobin 100g/l, WBC
38 $7.2 \times 10^9/l$, platelets $800 \times 10^9/l$). Neutrophils were $4.95 \times 10^9/l$, eosinophils $0.21 \times 10^9/l$, monocytes
39 $0.14 \times 10^9/l$ and lymphocytes $1.9 \times 10^9/l$. No blast cell was present in the peripheral blood. There was no
40 spleno- or hepatomegaly. On marrow aspirate, only 8 metaphases showing a normal karyotype (46XX)
41 could be analysed, due to the lack of growth of an adequate number of metaphases and the poor cellularity
42 of the sample. FISH analysis was limited to the study of 5q and demonstrated 5q31 deletion in 12% of the
43 nuclei. Thus, additional aberrations could not be identified. BCR/ABL rearrangements (p210, p190) were
44 absent, while JAK2V617F mutation displayed an allele burden of 4.28%.

45
46 BM biopsy showed a 70% cellularity, slight dyserythropoiesis, moderate myeloid hyperplasia and marked
47 proliferation of the megakaryocytic lineage with some dysplasia. A few megakaryocytes were large with
48 hyperlobulated nuclei; others were medium-sized, with round and/or hypolobulated nuclei. There were 3%
49 CD34 positive blasts and moderate reticulin fibrosis (WHO MF-2). (Fig.1 a,b,c,e). A strong nuclear p53
50
51
52
53
54
55
56
57
58
59
60
61

immunostaining was detected in 2% hematopoietic cells (Fig.1 d). We proposed a diagnosis of MDS with del (5q) and JAK2^{V617F} mutation.

The patient did not receive any therapy. No organomegaly nor leukoerythroblastosis was reported during the course of the disease. Twenty-seven months later, she was admitted to the hospital because of persistent fever, severe anaemia and neutropenia (Hb level 7.5 g/l, WBC 2.3x10⁹/l, neutrophils 0.75x10⁹/l, platelets 137x10⁹/l). There were 5% blast cells in the peripheral blood.

Chromosome banding analysis showed: 46,XX [1] / 45,XX, -7, del(5)(q13q33), del(13)(q14q34) [7] / 45, idem, del(2)(p12) [2]. FISH analysis demonstrated -7, del(5)(q31), del(13)(q14) (80%) without BCR/ABL, AML1/ETO, PML/RARA, inv(16), MLL(11q23) translocation and +8. Molecular analysis didn't identify FLT3 (ITD, D835), NPM1 (exon 12) or MLL-PTD mutations. RQ-PCR (real-time quantitative polymerase chain reaction) detected 4,164 WT1 copies/10⁴ ABL copies and 55.6% JAK2^{V617F} mutation load. p53 sequencing analysis of exons 2-11 showed a c.742C>T, p.R248W mutation in exon 7, that is considered a missense deleterious mutation.

BM demonstrated marked dyserythro-, dysgranulo- and dysmegakaryopoiesis, diffuse reticulin fibrosis and excess (25%) of CD34, CD117, CD33 and MPO positive blasts. (Fig.1 f,g,h,i,l). Strong nuclear p53 immunostaining was found in more than 20% of hematopoietic cells, including some blasts (Fig.1 m).

A diagnosis of AML with myelodysplasia-related changes was established. Induction therapy with fludarabine, cytarabine and idarubicin failed; reinduction therapy with clofarabine and cytarabine was then performed. However, the disease still persisted in a control BM biopsy performed three months later.

Contrary to previous reports [4,5], our case of del (5q) with JAK2^{V617F} mutation transformed to AML. MDS with isolated del(5q) has a very long median survival (145 months) and a low rate of transformation (<10%) to AML [1]. On the contrary, our case transformed to AML in 27 months only: it is possible that the simultaneous presence of del (5q), JAK2^{V617F} mutation and expression of p53 accelerated leukemic transformation. Indeed, a strong p53 immunostaining in >1% of bone marrow progenitor cells is known to be significantly associated with higher acute myeloid leukemia risk [7]. The percentage of strongly p53 positive BM cells was 2% at the time of the initial biopsy but more than 20% at the time of the leukemic transformation and included some blasts. Sequencing confirmed a p53 mutation. Therefore, it is possible that p53 mutation contributed to the unfavourable course of this case.

Moreover, the increase of JAK2^{V617F} mutation load (10x of the initial value) can also explain the high number of large megakaryocytes with hyperlobulated or cloudy nuclei, typical of a MPN disease, that were appreciated in the BM biopsy performed at the time of the leukemic transformation.

WHO recommends to classify patients with isolated del (5q) and JAK2^{V617F} mutation in the MDS category rather than in the MDS/MPN category [1].

However, the present case at diagnosis showed morphological features either of MDS and MPN. Furthermore, in the following transformation into AML, some morphological features of MPN were retained (large megakaryocytes with hyperlobulated or cloudy nuclei), together with myelodysplasia related changes (marked dyserythro-, dysgranulo- and dysmegakaryopoiesis).

Therefore, on the basis of the clinical and pathological features of the present case, we suggest that it would be more appropriate to classify MDS with del (5q) and JAK2^{V617F} mutation in the WHO MDS/MPN category rather than in the MDS category.

1 All procedures followed were in accordance with the ethical standards of the local institutional responsible
2 committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
3 Informed consent was obtained from the patient for being included in the study.

4 The authors declare that they have no conflict of interest.
5
6
7
8
9

10 11 12 References

- 13
14
15 1) Hasserjian RP, Le Beau MM, List AF, Bennett JM, Thiele J (2008) Myelodysplastic syndrome with isolated
16 del(5q). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW (eds) WHO
17 Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn, IARC Press, Lyon, p. 102.
18
19 2) Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008
20 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia* 22:14-22.
21
22 3) Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, Kiladjian JJ, Varkonyi J, Antunovic P,
23 Westwood NB, Arno MJ, Mohamedali A, Gaken J, Kontou T, Czepulkowski BH, Twine NA, Tamaska J, Csomer
24 J, Benedek S, Gattermann N, Zipperer E, Giagounidis A, Garcia-Casado Z, Sanz G, Mufti GJ (2006) The JAK2
25 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone
26 marrow. *Leukemia* 20:1319-1321.
27
28 4) Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA,
29 Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A (2010) WHO-defined 'myelodysplastic syndrome with
30 isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of
31 JAK2, MPL and IDH mutations. *Leukemia* 24:1283-1289.
32
33 5) Geyer JT, Verma S, Mathew S, Wang YL, Racchumi J, Espinal-Witter R, Subramaniyam S, Knowles DM,
34 Orazi A (2013) Bone marrow morphology predicts additional chromosomal abnormalities in patients with
35 myelodysplastic syndrome with del(5q). *Hum Pathol* 44:346-356.
36
37 6) Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, La Rocca F, Marziano G, Lalinga AV,
38 Fabiani E, Voso MT, Scaravaglio P, Mecucci C, D'Arena G (2014) Myelodysplastic disorders carrying both
39 isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. *Oncol*
40 *Targets Ther* 7:1043-1050.
41
42 7) Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D,
43 Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-
44 Lindberg E (2014) p53 protein expression independently predicts outcome in patients with lower-risk
45 myelodysplastic syndromes with del(5q). *Haematologica* 99:1041-1049.
46
47
48
49
50
51
52
53

54 Legends

55
56
57 Fig.1 Bone marrow biopsies of myelodysplastic syndrome with isolated del (5q) and JAK2V617F mutation
58 (A,B,C,D,E) and acute myeloid leukaemia with myelodysplasia-related changes (F,G,H,I,L).
59
60
61
62
63
64
65

1 a Slight dyserythropoiesis, moderate myeloid hyperplasia and marked proliferation of the megakaryocytic
2 lineage with some dysplasia (H&E). b Large megakaryocytes with hyperlobulated nuclei and medium-sized
3 megakaryocytes with round and/or hypolobulated nuclei (Dominici). c Moderate reticulin fibrosis (WHO
4 MF-2) (Gomori). d Strong nuclear p53 immunostaining in a few hematopoietic cells. e Dyserythropoiesis is
5 well shown by CD71 immunostaining.
6

7 f Hypercellular marrow with marked dyserythro-, dysgranulo- and dysmegakaryopoiesis and numerous
8 blasts (H&E). g A few micromegakaryocytes and one large megakaryocyte with hyperlobulated nucleus
9 (Dominici). h Diffuse reticulin fibrosis (Gomori). i CD34 immunopositive blasts. l CD117 immunopositive
10 blasts. m Strong nuclear p53 immunostaining in numerous hematopoietic cells, including some blasts.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure

